'Dis­crim­i­na­to­ry and dan­ger­ous': Phar­ma com­pa­nies and ad­vo­cates slam Texas judge's HIV cov­er­age de­ci­sion

3 years ago
Pharma
Law

Go­ing be­yond pro­tein degra­da­tion, a new Broad start­up kicks in­to gear to fix pro­tein func­tion­al­i­ty

3 years ago
Financing
Startups

Block­buster fran­chise ex­pands: Re­gen­eron shares spike on new high-dose Eylea da­ta

3 years ago
Pharma

A long Covid col­lab­o­ra­tive kicks off with $15M to study caus­es of lin­ger­ing dis­ease, con­duct clin­i­cal tri­als

3 years ago
Coronavirus

#ES­MO22: Seagen builds case for Pad­cev-Keytru­da com­bo in front-line blad­der can­cer

3 years ago
R&D

Aus­tralian CRO makes a move across the Pa­cif­ic for US ac­qui­si­tion

3 years ago
Deals
Outsourcing

Thanks for Nodus-ing: Basilea hands off pre­clin­i­cal on­col­o­gy pro­gram for $248M in on­go­ing an­ti-in­fec­tives piv­ot

3 years ago
Deals
R&D

Longer-last­ing Botox com­peti­tor nabs FDA ap­proval — can it com­pete with Ab­b­Vie's $2B cash cow?

3 years ago
Pharma

How sub can you sub­set? Eras­ca shores up case for test­ing its two lead can­di­dates in com­bo

3 years ago
R&D

Or­ca Bio looks to in­crease its cell ther­a­py man­u­fac­tur­ing ca­pac­i­ty with a new fa­cil­i­ty in Sacra­men­to

3 years ago
Cell/Gene Tx
Manufacturing

In­no­va­tion En­deav­ors doles out first in­vest­ment in the Joel Dud­ley era, with seed fund­ing for a small mol­e­cule ...

3 years ago
Financing
Startups

With first drug on the mar­ket, Ar­cutis forks over $16M cash for a buy­out

3 years ago
Deals

#ES­MO22: Re­lay Ther­a­peu­tics joins the win­ner's cir­cle this week­end as up­dat­ed can­cer da­ta win ap­plause

3 years ago
R&D

Al­ny­lam spells out its APOL­LO-B win for patisir­an — but just how good is it?

3 years ago
R&D

Ad­comm votes 7-2 in fa­vor of Amy­lyx's ALS drug on sec­ond take. But first the co-CEOs had to make a pledge

3 years ago
Pharma
FDA+

#ES­MO22: Af­ter day filled with in­vestor, GSK ap­petite, Spring­Works brings out the da­ta for can­cer drug near­ing FDA

3 years ago
Financing
Deals

#ES­MO22: Trail­ing Roche’s Tecen­triq, im­mune check­point ther­a­pies meet un­treat­ed liv­er can­cer with mixed re­sults

3 years ago
R&D

#ES­MO22: Trodelvy's long-await­ed sur­vival da­ta in breast can­cer are fi­nal­ly in — and bet­ter than ex­pect­ed

3 years ago
R&D

#ES­MO22: Out­side liv­er can­cer, Keytru­da notch­es key win in neoad­ju­vant set­ting but flops in head and neck tu­mors

3 years ago
R&D

#ES­MO22: Bris­tol My­ers spells out kid­ney can­cer flop for Op­di­vo/Yer­voy com­bo — but can a triplet catch on?

3 years ago
R&D

#ES­MO22: Mi­rati vs. Am­gen: Scrap­py KRAS G12C con­tender out­per­forms its gi­ant ri­val in col­orec­tal can­cer

3 years ago
R&D

On the heels of un­prompt­ed EMA re­view of Covid drug, FDA sched­ules ad­comm for po­ten­tial EUA

3 years ago
FDA+
Coronavirus

New study re­veals the ex­tent to which drug­mak­ers use con­di­tion-spe­cif­ic char­i­ties to in­duce spend­ing on cost­ly drugs

3 years ago
Pharma
Law

Genen­tech, No­var­tis re-up chron­ic hive cam­paign with celebri­ty co­me­di­an spokesper­son

3 years ago
Pharma
Marketing
First page Previous page 460461462463464465466 Next page Last page
A service from the Financial Times